Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction...
Transcript of Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction...
![Page 1: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/1.jpg)
Why Pharmaceutical Clinical Trials
Struggle to Succeed?
Cyntegrity, 2015
Artem Andrianov, PhD, MBA
Cyntegrity’s Presentation for Potential Investors
![Page 2: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/2.jpg)
WHO ARE WE?
2
![Page 3: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/3.jpg)
WHO ARE WE?
Team with 10+ years of experience in clinical data analysis 20+ analyzed clinical trials Over 100+ supported clinical trials for big pharma OverRead(Central Lab) and Data Cleaning services Scientific research together with academia Partnerships with local and global CROs
3
![Page 4: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/4.jpg)
Clinical Data Quality
Data Mining
Risk & Cost Reduction Strategy
4
OUR STRATEGY
![Page 5: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/5.jpg)
Our Partners and Customers in RbM already
5
![Page 6: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/6.jpg)
6
Cyntegrity - winner of the Hessen Model-Project Funding with the Project
“Process Innovation in Clinical Trial Monitoring”
German Government Research Funding
![Page 7: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/7.jpg)
WHAT PROBLEM WE TACKLE?
7
![Page 8: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/8.jpg)
Cost of Outsourcing by Function In Clinical Research
Major cost-saving potential
![Page 9: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/9.jpg)
FDA Success by Phase (LOA=Likelihood Of Approval)
Source: Nature Biotechnology9
Consequence: Budget and regulatory pressureCost optimization is needed!
![Page 10: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/10.jpg)
R&D returns have nearly halved over the last 10 years.
10
![Page 11: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/11.jpg)
11
Risk Potential and Its Assessment
Research
• research goal
• statistical significance
• prove of efficacy
Project Management
• budget,
• timelines,
• targets
Potential risk may arise
from the budget, milestones
and activities
The probability of
occurrence can be
estimated
Usually an incoming risk
affects the time course and
thus to the costs
![Page 12: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/12.jpg)
Internal and External Risks
Internal Risks
Company
External Risks
12
![Page 13: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/13.jpg)
Clinical Trials Challenges
Unskilled Project Manager
Unproductive Team Complexity of
Protocol
Dilemma ‘Project completion targets’ vs. ‘Eligibility of the
volunteers’
Poor training & poor verification
Ethical Issues
Data Quality
Unskilled Project Manager
Unproductive Team Complexity of
Protocol
Dilemma ‘Project completion targets’ vs. ‘Eligibility of the
volunteers’
Poor training & poor verification
Ethical Issues
Data Quality
13
?
![Page 14: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/14.jpg)
Alarm! + CAPA
14
![Page 15: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/15.jpg)
WHAT SOLUTION WE PROVIDE?
15
![Page 16: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/16.jpg)
Technical Solution
EarlyBird®
16
![Page 17: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/17.jpg)
17
Primary Outcome Measures
Protocol Compliance
Fraud
Key Risk Defense Strategy
Sponsor Specific Risks
Study Specific Risks
![Page 18: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/18.jpg)
Random Error Systematic Error Precision
EqualityEquality
18
![Page 19: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/19.jpg)
Technology plays a critical role in effective risk-based monitoring.
However, the monitoring team is equally important.
![Page 20: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/20.jpg)
Result 1: Site Visits Optimization
High-Risk Sites
Medium-Risk Sites
Low-Risk Sites
Optimize On-Site Monitoring
20
![Page 21: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/21.jpg)
Result 2: Absolute Data Quality
EqualityEquality21
![Page 22: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/22.jpg)
Result 3: Continuous Improvement
22
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6
![Page 23: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/23.jpg)
Result 3: Effective Communication and Knowledge Sharing within Team and among Trial Groups
Internal Risk-Chat Internal Ticketing SystemRisk Mitigation To-Do plan
Slide 23 of 9
![Page 24: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/24.jpg)
Distributions and Properties Variables
Proportion of missing values Means Global variances within patient
variances Proportion of week days Proportions of Outliers Correlation between variables Event counts
Applied Statistical Methods
24
![Page 25: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/25.jpg)
WHAT MAKES US UNIQUE?
25
Umbrella Principle
Undependability
Technological Innovation
Willingness to share
Science Orientation
![Page 26: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/26.jpg)
Market Potential
Sector: Technology
Industry: Healthcare
Information
Services
Industry Statistics
Price / Earnings: 55.3
Price / Book: 20.7
Net Profit Margin (mrq): 8.8%
Price To Free Cash Flow
(mrq):
62.9
Return on Equity: 10.6%
Total Debt / Equity: 63.6
26
Source: yahoo finance 24. Nov 2013 (http://biz.yahoo.com/ic/825.html)
Cyntegrity operates on the Healthcare Information Services, with
the market capitalization $40 Bn, with the forecast of CAGR
22.5% only in U.S. during 2012-2014.
CAGR – Compound annual growth rateSource: U.S. Healthcare IT Market Analysis (Oct, 2011)http://www.rncos.com/Report/IM321_fig.htm
Number of registered Studies over time. Source: ClinicalTrials.gov
![Page 27: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/27.jpg)
Who is our Customer?
Client Value Proposition
Contract research organization
(CROs)
Competitive advantage on the market in offering
advanced quality assurement as an additional service
for pharmaceutical corporations.
Additionally optimisation & reduction of the costs of
clinical monitoring.
Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging
reputation, new quality standard within industry.
Service of sanity checks can become required in the
preparation to FDA audits, minimizing the risks of
audit findings.
Biotech Companies Optimization of clinical monitoring costs, mitigating
the risks with later identification of problem zones.
27
![Page 28: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/28.jpg)
Proven Value for Customer
28
![Page 29: Why Pharmaceutical Clinical Trials Struggle to Succeed? · Pharmaceutical Organizations Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within](https://reader036.fdocuments.us/reader036/viewer/2022081614/5fc7944b1bdf8635fc47b4fe/html5/thumbnails/29.jpg)
Irving Fisher (1867-1947)